Skip to main content
HOPA 2024 Main banner
Final Program


Program Book
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Full Schedule

  1. Home
  2. Full Schedule

Full Schedule

  • Wednesday, April 3, 2024
  • 7:00 AM – 8:00 AM ET
    CE Symposium: Optimizing JAK Inhibitor Therapy for Myelofibrosis: Insights for Oncology Pharmacists
  • 7:00 AM – 8:00 AM ET
    CE Symposium: Prescriptions for Successful Myeloma Care: Pharmacy Strategies for Delivering Effective Therapy With Antibody Platforms
  • 7:00 AM – 8:00 AM ET
    CE Symposium:Balancing Innovation and Implementation: A Comprehensive Approach to CAR T, Bispecific Antibodies, and Operational Efficiency in Multiple Myeloma
  • 8:00 AM – 12:00 PM ET
    Pre-conference: From Data to Decisions: A Masterclass in Critical Appraisal of Cancer Research
  • 12:00 PM – 1:00 PM ET
    Non-CE Symposium: How Is the Treatment of Patients With KRAS G12C-Mutated Advanced NSCLC Evolving?
  • 12:00 PM – 1:00 PM ET
    Non-CE Symposium: Brukinsa (zanubrutinib) for the treatment of adult patient with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
  • 12:00 PM – 1:00 PM ET
    Non-CE Symposium: Outcomes and Economic Impact of Treatment with CABLIVI®(caplacizumab-yhdp)
  • 1:15 PM – 2:30 PM ET
    Diving into DEI: Increasing Inclusivity and Fostering Diversity in Clinical Trials
  • 1:15 PM – 2:30 PM ET
    Updates in Hematology
  • 2:45 PM – 3:30 PM ET
    President's Welcome
  • 3:45 PM – 4:45 PM ET
    Platform Research Part 1 of 4: The REMEDY Trial: Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After High-Dose Cytarabine Consolidation Chemotherapy
  • 3:45 PM – 4:45 PM ET
    Platform Research Part 2 of 4: Post-Transplant Cyclophosphamide As GVHD Prevention After Myeloablative Conditioning
  • 3:45 PM – 4:45 PM ET
    Platform Research Part 3 of 4: Survey of PGY-2 Oncology RPDs To Assess Resources and Effects on Burnout
  • 3:45 PM – 4:45 PM ET
    Platform Research Part 4 of 4: Predictive Factors of Dose Reduction Among Patients Treated With Palbociclib
  • 3:45 PM – 4:45 PM ET
    Updates in Hodgkin Lymphoma and the Role of the Pharmacist in Management of Toxicities
  • 3:45 PM – 4:45 PM ET
    Waiting For The Rain: Practical Strategies And Ethical Considerations During Anticancer Drug Droughts
  • 4:45 PM – 7:00 PM ET
    Exhibit Hall Welcome Reception and Industry Encore Posters
  • 5:30 PM – 6:30 PM ET
    Non-CE Symposium: Managing Patients with locally advanced or metastatic KRAS G12C-mutated NSCLC
  • 5:30 PM – 6:30 PM ET
    Non-CE Symposium: Planning for Treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Case-Based Symposium on Care Team Preparation and Patient Management
  • 6:00 PM – 8:00 PM ET
    AC24 Service Project: HOPA CAN Help Prevent HIV
  • Thursday, April 4, 2024
  • 6:15 AM – 7:30 AM ET
    5K Fun Run
  • 7:00 AM – 8:00 AM ET
    Non-CE Symposium: Key Considerations for Operationalizing Bispecifics in Relapsed or Refractory Multiple Myeloma
  • 7:00 AM – 8:00 AM ET
    Non-CE Symposium: Essentials for Pharmacists: A Treatment Option for Relapsed or Refractory Multiple Myeloma From Pfizer
  • 7:00 AM – 8:00 AM ET
    Non-CE Symposium: Managing Myelofibrosis: A Pharmacist’s Perspective
  • 7:00 AM – 8:00 AM ET
    Special Interest Group (SIG) - Geriatric
  • 7:00 AM – 8:00 AM ET
    Special Interest Group (SIG) - New Practitioner
  • 7:00 AM – 8:00 AM ET
    Special Interest Group (SIG) - Pediatrics
  • 7:00 AM – 8:00 AM ET
    Special Interest Group (SIG) - Precision Health in Oncology
  • 7:00 AM – 8:00 AM ET
    Special Interest Group (SIG) - Transplant & Cellular Therapy
  • 8:15 AM – 9:30 AM ET
    CAR T-Cell Breakthroughs in Lymphoma and Myeloma: Balancing Efficacy and Safety
  • 8:15 AM – 9:30 AM ET
    Moving Beyond One Size Fits All for Solid Tumors: Updates in Biomarker Driven Therapies
  • 9:40 AM – 10:40 AM ET
    1 - To Transplant or Not to Transplant: Current Treatment Approaches for Mantle Cell Lymphoma
  • 9:40 AM – 10:40 AM ET
    2 - Baby Steps: Updates in the Treatment of Infant Leukemia
  • 9:40 AM – 10:40 AM ET
    3 - Advances in Targeted Therapies for Gastrointestinal Malignancies
  • 9:40 AM – 10:40 AM ET
    4 - Targeting HER2 Alterations in Patients With Non-Breast/Non-Gastric Cancers
  • 9:40 AM – 10:40 AM ET
    5 - Show Me the Money: Optimizing the Electronic Medical Record (EMR) to Improve Biosimilar Utilization and Pharmacy Reimbursement
  • 9:40 AM – 10:40 AM ET
    6 - Cannabinoids and the Oncology Patient: Pearls for Pharmacists
  • 10:50 AM – 11:50 AM ET
    Member Awards & Business Meeting
  • 11:50 AM – 2:15 PM ET
    Exhibit Hall and Lunch
  • 12:00 PM – 1:00 PM ET
    CE Symposium: Advancements in Early-Stage Breast Cancer: The Role of Oncology Pharmacists in Treatment Optimization
  • 12:00 PM – 1:00 PM ET
    CE Symposium: Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise
  • 12:00 PM – 1:00 PM ET
    CE Symposium: What’s New in NSCLC Therapies? Key Takeaways for Your Pharmacy Practice
  • 12:00 PM – 1:00 PM ET
    Leadership Development Roundtable: Career Ladders and Professional Development Plans
  • 12:00 PM – 1:00 PM ET
    Special Interest Group (SIG) - Academia
  • 12:00 PM – 1:00 PM ET
    Special Interest Group (SIG) - Administration
  • 12:00 PM – 1:00 PM ET
    Special Interest Group (SIG) - Epic (Beacon) Users
  • 12:00 PM – 1:00 PM ET
    Special Interest Group (SIG) - Gynecologic Oncology
  • 12:00 PM – 1:00 PM ET
    Special Interest Group (SIG) - Specialty Pharmacy
  • 1:00 PM – 2:00 PM ET
    Annual Advocacy Update
  • 2:15 PM – 3:30 PM ET
    Debating the Incorporation of Novel Therapies in Front-Line Acute Lymphoblastic Leukemia Treatment
  • 2:15 PM – 3:30 PM ET
    The Great Financial Debate: Cost vs Margin for Cancer Care Drugs
  • 3:45 PM – 4:45 PM ET
    New Practitioner’s Guide to Navigating Your Career
  • 3:45 PM – 4:45 PM ET
    Nuances in Neuro-Oncology: Glioma Treatment Advances and New Diagnostic
  • 3:45 PM – 4:45 PM ET
    REACHing for ROCKstars –iNTEGRATing Updates in Chronic Graft Versus Host Disease
  • 4:45 PM – 7:30 PM ET
    Exhibit Hall Evening Reception
  • 5:00 PM – 6:00 PM ET
    Diversity + Belonging Reception
  • 5:00 PM – 7:30 PM ET
    E-Poster Presentations: Completed Research and Trainee Top Ten
  • 5:30 PM – 6:30 PM ET
    Non-CE Symposium: Review of Evidence-Based Data for an Antibody-Drug Conjugate in Combination With a PD-1 Inhibitor for 1L la/mUC
  • 5:30 PM – 6:30 PM ET
    Non-CE Symposium: EMERALD study update: Exploring the safety and efficacy data in patients with ER+/HER2, ESR1-mutated mBC, including data from subgroup analyses
  • 6:00 PM – 8:00 PM ET
    IRC Reception (Invite Only)
  • Friday, April 5, 2024
  • 6:30 AM – 7:30 AM ET
    Yoga
  • 7:00 AM – 8:00 AM ET
    CE Symposium: Maximizing Efficacy and Minimizing Toxicity of ADCs Targeting HER2, HER3 and TROP2: Strategies for Oncology Pharmacists
  • 7:00 AM – 8:00 AM ET
    CE Symposium: Navigating Chronic Lymphocytic Leukemia Therapy and Cardiovascular Comorbidities: Clinical Recommendations and Safety Measures
  • 7:00 AM – 8:00 AM ET
    CE Symposium: Optimizing Bispecific Antibody Utilization in Non-Hodgkin Lymphoma: Addressing Challenges in Community-Based Care
  • 7:00 AM – 8:00 AM ET
    Special Interest Group (SIG) - Ambulatory
  • 7:00 AM – 8:00 AM ET
    Special Interest Group (SIG) - Breast Cancer
  • 7:00 AM – 8:00 AM ET
    Special Interest Group (SIG) - Cerner Oncology Users
  • 7:00 AM – 8:00 AM ET
    Special Interest Group (SIG) - Industry Professionals
  • 8:15 AM – 9:30 AM ET
    New Flavors: Bites in Hematologic Malignancies
  • 8:15 AM – 9:30 AM ET
    Pharmacology and Clinical Application of Complement Inhibitors
  • 9:40 AM – 10:40 AM ET
    1 - Ethical Dilemmas in Oncology Pharmacy: When Science and Morals Collide
  • 9:40 AM – 10:40 AM ET
    2 - The Gene Therapy Odyssey: Preparing the Pharmacist for New Horizons
  • 9:40 AM – 10:40 AM ET
    3 - Bispecifics in Lymphoma
  • 9:40 AM – 10:40 AM ET
    4 - Taking a Bite Out of Myeloma: The Role of Bi-Specific Antibodies in the Treatment of Relapsed/Refractory Multiple Myeloma
  • 9:40 AM – 10:40 AM ET
    5 - Updates in the Management of Endometrial Cancer
  • 9:40 AM – 10:40 AM ET
    6 - Expanding the Use of CDK4/6 Inhibitors to Early-Stage Breast Cancer Treatment
  • 10:50 AM – 11:50 AM ET
    John G. Kuhn Keynote Address: Dr. Glaucomflecken "Wife & Death & Comedy"
  • 11:50 AM – 2:15 PM ET
    Exhibit Hall and Lunch
  • 12:00 PM – 1:00 PM ET
    Non-CE Symposium: Explore the current data that could help you recognize/assess candidates for a CDK4 & 6 inhibitor.
  • 12:00 PM – 1:00 PM ET
    Non-CE Symposium: Practical Management of AML with a BCL-2 Inhibitor
  • 12:00 PM – 1:00 PM ET
    Non-CE Symposium: Understanding the role of pharmacists in the management of Low-risk Myelodysplastic Syndromes (MDS)
  • 12:00 PM – 1:00 PM ET
    Special Interest Group (SIG) - Classical Hematology
  • 12:00 PM – 1:00 PM ET
    Special Interest Group (SIG) - Investigational Drug Services (IDS)
  • 12:00 PM – 1:00 PM ET
    Special Interest Group (SIG) - Residency Program Directors (RPD)
  • 12:00 PM – 1:00 PM ET
    Special Interest Group (SIG) - Trainee
  • 12:00 PM – 2:00 PM ET
    Poster Session: Trainee Research
  • 2:15 PM – 3:00 PM ET
    Incoming President's Remarks
  • 3:15 PM – 4:15 PM ET
    Aiming for the Bullseye: Updates in Pediatric Solid Tumor Precision Medicine
  • 3:15 PM – 4:15 PM ET
    Buzzworthy Bladder Breakthroughs: Updates in Metastatic Bladder Cancer
  • 6:00 PM – 9:00 PM ET
    HOPA's 20th Anniversary Gala
  • Saturday, April 6, 2024
  • 7:00 AM – 8:00 AM ET
    CE Symposium: Enhancing Bruton Tyrosine Kinase Inhibitor Outcomes in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: A Pharmacist's Roadmap to Success
  • 7:00 AM – 8:00 AM ET
    CE Symposium: New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes (LR-MDS): Bridging Clinical Innovation and Practice
  • 8:15 AM – 9:15 AM ET
    Up to My Neck (In Head and Neck Cancer Updates)
  • 8:15 AM – 9:15 AM ET
    1 - Clinical Pearl 1: Challenging the Recognition and Treatment Management for HER2-low Breast Cancer
  • 8:15 AM – 9:15 AM ET
    2 - Clinical Pearl 2: Best Practices – Management of Alpelisib-Induced Hyperglycemia
  • 8:15 AM – 9:15 AM ET
    3 - Clinical Pearl 3: Metastatic Castrate Resistant Prostate Cancer in a State of (Homologous Recombination) Repair: Navigating PARPi Therapy Selection
  • 9:25 AM – 10:25 AM ET
    1 - To Treat or Not To Treat? The Role of Immunotherapy in Non Small Cell Lung Cancer (NSCLC) With Oncogenic Drivers
  • 9:25 AM – 10:25 AM ET
    2 - Research Grant, Part 1: Oncology Pharmacist-Driven Symptom Monitoring System Uncovered Health Disparities in Minoritized Patients Receiving Anticancer Therapies
  • 9:25 AM – 10:25 AM ET
    3 - Research Grant, Part 2: Pharmacist Monitoring of Patient-Reported Outcome Measures (PROMs) for Oral Oncolytics
  • 9:25 AM – 10:25 AM ET
    4 - Updates in Chronic Lymphocytic Leukemia: Sequencing Versus Combination Therapy of Small Molecule Inhibitors
  • 10:35 AM – 11:35 AM ET
    Collaborative Practice in Clinical Trials: Reinforcements for the Crisis in Clinical Research
  • 10:35 AM – 11:35 AM ET
    Igniting Breakthroughs in Pharmacogenetics & Genomics: Unveiling the Pathogenic Potential of VUS Through DEI Enhancement
  • 11:45 AM – 12:45 PM ET
    Non-CE Symposium: Harnessing the Power of Human Immunity
  • 11:45 AM – 12:45 PM ET
    Non-CE Symposium: Long-Term Clinical Trial Results for a BTKi in the Treatment of CLL/SLLa